Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients
Jacopo Sabbatinelli(Marche Polytechnic University), Angelica Giuliani(Marche Polytechnic University), Giulia Matacchione(Marche Polytechnic University), Silvia Latini(Marche Polytechnic University), Noemi Laprovitera(University of Bologna), Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni(Marche Polytechnic University), Marianna Pavani(Marche Polytechnic University), Marco Moretti(Azienda Ospedaliero Universitaria Ospedali Riuniti), Armando Gabrielli(Marche Polytechnic University), Antonio Domenico Procopio(Marche Polytechnic University), Manuela Ferracin(Istituto Nazionale di Riposo e Cura per Anziani), Massimiliano Bonafè(University of Bologna), Fabiola Olivieri(Marche Polytechnic University)
Cited by 115Open Access
Abstract
Related Papers
<i>miR-146a</i> is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Mark Boldin, Konstantin D. Taganov, Dinesh S. Rao et al.|The Journal of Experimental Medicine|2011|866